Key points are not available for this paper at this time.
Phase 3 PRIME/PRIME2 trials independently demonstrated efficacy and an acceptable safety profile of dupilumab adults with moderate-to-severe prurigo nodularis.
Yosipovitch et al. (Wed,) studied this question.